Therapeutic efficacy of Pioglitazone for Non-Alcoholic Fatty Liver Desease (NAFLD) [non-alcoholic steatohepatitis] patients with impaired glucose tolerance or type 2 diabetes.

Trial Profile

Therapeutic efficacy of Pioglitazone for Non-Alcoholic Fatty Liver Desease (NAFLD) [non-alcoholic steatohepatitis] patients with impaired glucose tolerance or type 2 diabetes.

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Feb 2012

At a glance

  • Drugs Pioglitazone (Primary) ; Antihyperglycaemics
  • Indications Non-alcoholic steatohepatitis
  • Focus Therapeutic Use
  • Acronyms TOPIC
  • Most Recent Events

    • 29 Feb 2012 Status changed from recruiting to completed as reported by University Hospital Medical Information Network - Japan.
    • 27 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top